Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of 28 Weeks to Investigate the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight Followed by a 32-Week Extension (VESPER-1)

NCT06712836 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06712836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06712836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of 28 Weeks to Investigate the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight Followed by a 32-Week Extension (VESPER-1)
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
October 9, 2024
Completion date
April 30, 2026
Enrollment
239 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight or obesity